Literature DB >> 21735473

Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells.

Wen Sun1, Jin Ding, Kun Wu, Bei-Fang Ning, Wen Wen, Han-Yong Sun, Tao Han, Lei Huang, Li-Wei Dong, Wen Yang, Xing Deng, Zhong Li, Meng-Chao Wu, Gen-Sheng Feng, Wei-Fen Xie, Hong-Yang Wang.   

Abstract

UNLABELLED: Gankyrin is a critical oncoprotein overexpressed in human hepatocellular carcinoma (HCC). However, the mechanism underlying gankyrin-mediated hepatocarcinogenesis remains elusive. Herein, we provide evidence that gankyrin expression was progressively elevated in liver fibrosis, cirrhosis, and HCC. Levels of gankyrin expression were closely associated with the dedifferentiation status of hepatoma in patients. Decrease of hepatocyte characteristic markers and increase of cholangiocyte-specific markers were observed in rat primary hepatocytes with enforced gankyrin expression and diethylnitrosamine (DEN)-triggered rat hepatocarcinogenesis. Overexpression of gankyrin also attenuated the hepatic function of primary hepatocytes, which further suggests that gankyrin promotes the dedifferentiation of hepatocytes. Moreover, elevated expression of gankyrin closely correlated with the expression of HCC stem/progenitor cell markers in DEN-triggered hepatocarcinogenesis and human HCCs. Hepatoma cells derived from suspension-cultured spheroids exhibited a higher gankyrin level, and enforced gankyrin expression in hepatoma cells remarkably enhanced cluster of differentiation (CD)133, CD90, and epithelial cellular adhesion molecule expression, indicating a role of gankyrin in hepatoma cell dedifferentiation and the generation of hepatoma stem/progenitor cells. In contrast, down-regulation of gankyrin in hepatoma cells by lentivirus-mediated microRNA delivery significantly improved their differentiation status and attenuated malignancy. Interference of gankyrin expression in hepatoma cells also diminished the proportion of cancer stem/progenitor cells and their self-renewal capacity. Furthermore, gankyrin was found to bind hepatocyte nuclear factor 4α (HNF4α), which determines hepatocyte differentiation status and enhances proteasome-dependent HNF4α degradation in hepatoma cells. The inverse correlation of gankyrin and HNF4α was further confirmed in primary hepatocytes, DEN-induced hepatocarcinogenesis, and human HCCs.
CONCLUSION: Gankyrin-mediated dedifferentiation of hepatocytes and hepatoma cells via, at least partially, down-regulation of HNF4α facilitates HCC development, and interference of gankyrin expression could be a novel strategy for HCC prevention and differentiation therapy.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21735473     DOI: 10.1002/hep.24530

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  21 in total

1.  PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression.

Authors:  Tao Luo; Jing Fu; An Xu; Bo Su; Yibing Ren; Ning Li; Junjie Zhu; Xiaofang Zhao; Rongyang Dai; Jie Cao; Bibo Wang; Wenhao Qin; Jinhua Jiang; Juan Li; Mengchao Wu; Gensheng Feng; Yao Chen; Hongyang Wang
Journal:  Autophagy       Date:  2015-04-23       Impact factor: 16.016

2.  p38α inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species.

Authors:  Toshiharu Sakurai; Masatoshi Kudo; Atsushi Umemura; Guobin He; Ahmed M Elsharkawy; Ekihiro Seki; Michael Karin
Journal:  Cancer Res       Date:  2012-12-27       Impact factor: 12.701

Review 3.  Gankyrin as a potential target for tumor therapy: evidence and perspectives.

Authors:  Haixai Li; Junyan Zhang; Cheng Zhen; Baojun Yang; Limin Feng
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

4.  FXR-Gankyrin axis is involved in development of pediatric liver cancer.

Authors:  Leila Valanejad; Kyle Lewis; Mary Wright; Yanjun Jiang; Amber D'Souza; Rebekah Karns; Rachel Sheridan; Anita Gupta; Kevin Bove; David Witte; James Geller; Gregory Tiao; David L Nelson; Lubov Timchenko; Nikolai Timchenko
Journal:  Carcinogenesis       Date:  2017-07-01       Impact factor: 4.944

Review 5.  Gankyrin as a potential therapeutic target for cancer.

Authors:  Chongchong Wang; Li Cheng
Journal:  Invest New Drugs       Date:  2017-05-19       Impact factor: 3.850

6.  TGF-β1 signaling pathway serves a role in HepG2 cell regulation by affecting the protein expression of PCNA, gankyrin, p115, XIAP and survivin.

Authors:  Xin-Hong Wang; Zhi-Guo Chen; Rui-Ling Xu; Cheng-Qian Lv; Jing Liu; Bing Du
Journal:  Oncol Lett       Date:  2017-03-06       Impact factor: 2.967

7.  Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication.

Authors:  Irena Misiewicz-Krzeminska; María E Sarasquete; Dalia Quwaider; Patryk Krzeminski; Fany V Ticona; Teresa Paíno; Manuel Delgado; Andreia Aires; Enrique M Ocio; Ramón García-Sanz; Jesús F San Miguel; Norma C Gutiérrez
Journal:  Haematologica       Date:  2012-10-25       Impact factor: 9.941

8.  Association of gankyrin and stemness factor expression in human colorectal cancer.

Authors:  Hiromasa Mine; Toshiharu Sakurai; Hiroshi Kashida; Shigenaga Matsui; Naoshi Nishida; Tomoyuki Nagai; Satoru Hagiwara; Tomohiro Watanabe; Masatoshi Kudo
Journal:  Dig Dis Sci       Date:  2013-03-19       Impact factor: 3.199

Review 9.  Gankyrin regulates cell signaling network.

Authors:  Xinxin Wang; Bin Jiang; Yanjie Zhang
Journal:  Tumour Biol       Date:  2016-01-27

10.  Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer.

Authors:  Yanjun Jiang; Polina Iakova; Jingling Jin; Emily Sullivan; Vladislav Sharin; Il-Hwa Hong; Sayee Anakk; Angela Mayor; Gretchen Darlington; Milton Finegold; David Moore; Nikolai A Timchenko
Journal:  Hepatology       Date:  2013-02-15       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.